MACROGENICS INC

MGNX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001125345

Price chart

Open-market purchases and sales by MGNX insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Aug 20, 20266:19 PM ETAug 19, 2026Peters Jeffrey StuartSenior VP, GC, and SecretarySSaleCommon Stock−31.11K$4.15−$129.09K0−100.0%SEC10b5-1
Aug 21, 2025Aug 19 – Aug 20, 2025HEIDEN WILLIAM KDirectorPPurchaseCommon Stock+100K$1.5052+$150.52K111K+909.1%SEC
Feb 19, 2025Feb 15, 2025Smith Beth AnnVP, Controller & TreasurerSSaleCommon Stock−423$2.56−$1.08K9.53K−4.2%SEC
Apr 8, 2024Apr 4, 2024Peters Jeffrey StuartSenior VP and General CounselSSaleCommon Stock−51.4K$15.5491−$799.15K0−100.0%SEC10b5-1
Mar 8, 2024Mar 6, 2024Peters Jeffrey StuartSenior VP and General CounselSSaleCommon Stock−19.63K$21.50−$421.94K8.9K−68.8%SEC10b5-1

The largest institutional positions in MGNX at the end of Q2 2026.

Institutions holding MGNX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
ARMISTICE CAPITAL, LLC5,006,752$23.13M0.64%−1,005,248−16.7%Reduced
BlackRock, Inc.4,679,229$21.62M0.00%+3,516,083+302.3%Added
VANGUARD CAPITAL MANAGEMENT LLC2,656,010$12.27M0.00%+2,157+0.1%Added
RENAISSANCE TECHNOLOGIES LLC2,632,750$12.16M0.02%−330,809−11.2%Reduced
ACADIAN ASSET MANAGEMENT LLC2,542,643$11.74M0.01%−1,357−0.1%Reduced